Financing ·
MDxHealth raises $20M via registered direct placement of over 44 million shares at $0.454 each
MDXHMDxHealth SA
MDxHealth SA reported a net loss of $20.4 million and revenue of $51.1 million for the six months ended June 30, 2026. The company discontinued its Resolve UTI testing business and closed its Plano, Texas laboratory in May 2026, classifying it as a discontinued operation with a net loss of $1.2 million. On August 13, 2026, MDxHealth completed a registered direct placement of 44,052,862 ordinary shares at $0.454 per share, raising $20 million in gross proceeds to address liquidity concerns. The company remains in non-compliance with Nasdaq's minimum bid price requirement, facing a compliance deadline of December 28, 2026. MDxHealth operates in the precision diagnostics industry, developing and commercializing genomic testing solutions for prostate cancer.